Navigation Links
Tea Found To Boost Insulin Production And Prevent Cataract,,

Diabetes is a multifactorial disorder that can lead to a multitude of complications if left untreated. A new research conducted on animal models suggests the possibility of using tea as a form of treatment for the chronic disorder. More specifically, //it has been found to prevent the incidence of cataracts, a significant health problem faced by majority of the diabetics worldwide.

Researchers developed special rats with diabetes. This provided a simulation of the health condition in humans. These diabetic rats were then fed green and black tea for a period of three months. Following this, the chemical composition of the blood and eye lenses of the diabetic rats was monitored.

At the end of the analysis, the results obtained showed a ray of hope, with both forms of tea effective in inhibiting cataract formation. The rats that belonged to the control group (were not given the tea) did not show any protective effect of the tea. This approximated to less than five cups of tea per day for a human being to observe a similar effect.

In another study conducted on black, green and oolong teas, the popular beverage was found to increase insulin activity by as much as 15 times in the fat cells that was extracted from rats.

The researchers believe that the protective effect of the tea in diabetic individuals could be due to the presence of an active compound found in tea, called epigallocatechin gallate. If the results are proved with conclusive evidence, then we might soon have a simple, relatively inexpensive way of treating diabetes and its related complications.
'"/>




Page: 1

Related medicine news :

1. Fluoride Found Effective in Osteoporosis
2. Implantable Contact Lens Found Safe and Effective
3. Cancer hazard Found With Animal-Based Nutrients
4. Processed Meat, Diabetes connection Found
5. Night Time Aspirin Regimen Found to Reduce Blood Pressure
6. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
7. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
8. Preventive Therapies Found to be More Effective in Managing Migraines
9. Common Cold Found to Fight Cancer
10. Circumcision Found To Prevent HIV Spread
11. Drug Found To Reduce The Transmission Of Herpes
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Tea Found Boost Insulin Production And Prevent Cataract

(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the ... released this new applicator in the United States as an upgrade to the CoolSmooth ... The original applicator required a 2 hour treatment time. The new CoolSmooth Pro ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... WASHINGTON, June 18 While Congressional debate is focused primarily ... many Americans remain concerned about how a mandate for private ... , , "We,re hearing politicians promise that ... to keep it. But what if the federal government ...
... , MUNDELEIN, Ill., June 18 Sysmex America today announced ... Award, presented by Premier Purchasing Partners, LP ... healthcare alliance . , , Premier contracts with ... 19 contracted suppliers to receive the Pinnacle Award. Winners are ...
... June 18 Vendormate, the market leader in vendor ... the role of president, effective immediately. Andy Monin, ... and developing strategic opportunities. , ... success of Vendormate, steadily guiding our processes, systems, and ...
... possible to determine which patients run a high risk of ... in patients with minimal memory impairment. This has been shown ... Sweden. The results have been published in the most ... . "The earlier we can catch Alzheimer,s disease, the ...
... millions of people each year, with costs reaching into ... challenge, Wound Care Certified professionals are becoming a growing ... The National Alliance of Wound Care (NAWC(R)), a ... credentialed over 7000 health care professionals as WCC(R)s (Wound ...
... to Vote on Merger Agreement with Pfizer - , , ... WYE ) today announced that it has filed a definitive proxy ... Meeting of Stockholders. Among other matters, stockholders will vote on ... was announced on January 26, 2009. , , ...
Cached Medicine News:Health News:Patient Advocacy Groups Urge Greater Focus on Patients' Choice and Privacy Rights in Health-Reform Debate 2Health News:Sysmex America Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Health News:Bill Hayes Promoted to President of Vendormate 2Health News:Cerebrospinal fluid shows Alzheimer's disease deterioration much earlier 2Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 2Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 3Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 4
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... June 11, 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced ... of its investigational non-peptide oral platelet growth,factor, ... that PROMACTA at 50-75mg once daily resulted ... and also,reduced bleeding in adult patients with ...
... Phase 1 Clinical Trial of SNS-595 in Acute,Leukemia ... June 11, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented,positive ... company's,anti-cancer product candidates, SNS-595 and SNS-032, at the ... Vienna,Austria. , Interim Results from Sunesis' Phase 1 ...
Cached Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6
... designed from the ground-up with ergonomic concerns ... and most adjustable observation tube on the ... every user can adjust the microscope to ... helps the operator maintain an upright, comfortable ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
... operates with a simple click of ... Direct the mouse cursor to the ... of the slide and the magnified ... Graphic User Interface (GUI) enables one-click ...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: